Cystic Fibrosis Clinical Trial
Official title:
Cystic Fibrosis Core Strengthening and Respiratory Exercise Program (CSREP)
The purpose of this project is to determine the short-term effects of a customized Core
Strengthening and Respiratory Exercise Program (CSREP) on children with cystic fibrosis (CF)
between the ages of 10 and 21 who are receiving outpatient care at Children's Hospitals and
Clinics of Minnesota. The CSREP, which will be provided by a physical therapist and a
physical therapist assistant, consists of specific breathing techniques and core
strengthening exercises, designed to improve rib cage mobility, pulmonary function, aerobic
capacity, posture, and core strength. Currently the CF population at Children's receives
physical therapy on an inpatient basis only.
The overall goal of this program is to prove the viability of an outpatient exercise program
for this population. Specific aims include:
- To customize a CSREP protocol per each patient
- To measure patient outcomes at baseline and six months
- To develop a satisfaction tool in order to measure patient experience and satisfaction
Study Design: Phase II clinical trial.
Objective: To determine whether a customized physical therapy exercise intervention titled
Core Strengthening and Respiratory Exercise Program (CSREP) clinically improves the
following outcome measures for children between the ages of 10 and 21 with cystic fibrosis:
pulmonary function, aerobic capacity, rib cage mobility, posture, and core strength, thus
warranting more extensive study and development.
Background: Previous research conducted in pediatric populations has focused on the effects
of aerobic training, anaerobic training, and strengthening of the extremities on the health
of children with cystic fibrosis. However, the disease process of cystic fibrosis
secondarily causes impairments in the musculoskeletal and nervous systems. No intervention
study aimed at positively impacting these systems has been done to date with children with
cystic fibrosis.
Methods: A 6-month CSREP will be customized to meet the specific needs of each participant.
During Part I of the program participants will attend weekly CSREP treatments for 4 to 6
weeks; in Part II they will attend monthly CSREP treatments over a five-month period. Each
session will last for 45-60 minutes. During these treatments, participants will be given
instruction on a daily home exercise program and will receive hands on physical therapy
interventions. Handouts with pictures and how-to instructions for assigned exercises will be
provided. Participants will be given calendars to track completion of home exercises and
level of compliance. During Part II, a researcher will call participants every week in order
to encourage compliance with the home exercise program and to provide clarification as
needed. All participants will continue to receive regular medical care as well as PT
treatments.
A respiratory therapist will perform the pulmonary function tests, a respiratory therapist
along with an exercise physiologist will perform the VO2max testing, and a physical
therapist will perform the physical therapy evaluation, including assessment of rib cage
mobility, core strength, and posture. Another physical therapist as well as a physical
therapist assistant will provide the physical therapy treatments, instruct the participants
in their home program, and make the weekly phone calls to all participants.
An experience survey will be designed to evaluate both satisfaction on a scale of 1 to 10
and self scoring of outcome measures including: respiratory function, cough strength,
activity tolerance, posture, and strength on a three point Likert scale of: 1) Got worse; 2)
Stayed the same; and 3) Got better. Additionally, the survey will include a question on the
likelihood of continuing with the home program after the study has ended. The survey will be
administered at 6 months upon completion of the program.
Relevance: The results of this inquiry as to the viability of the CSREP will prove relevant
to the above-mentioned patient outcomes within the cystic fibrosis population. The
customized CSREP protocol will provide a non-pharmacological outpatient treatment option
that can be completed on an outpatient basis, independently, in the patient's home.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |